Literature DB >> 19293950

Metabolic syndrome in people with schizophrenia: a review.

Marc DE Hert1, Vincent Schreurs, Davy Vancampfort, Ruud VAN Winkel.   

Abstract

Metabolic syndrome and other cardiovascular risk factors are highly prevalent in people with schizophrenia. Patients are at risk for premature mortality and overall have limited access to physical health care. In part these cardio-metabolic risk factors are attributable to unhealthy lifestyle, including poor diet and sedentary behaviour. But over recent years it has become apparent that antipsychotic agents can have a negative impact on some of the modifiable risk factors. The psychiatrist needs to be aware of the potential metabolic side effects of antipsychotic medication and to include them in the risk/benefit assessment when choosing a specific antipsychotic. He should also be responsible for the implementation of the necessary screening assessments and referral for treatment of any physical illness. Multidisciplinary assessment of psychiatric and medical conditions is needed. The somatic treatments offered to people with severe and enduring mental illness should be at par with general health care in the non-psychiatrically ill population.

Entities:  

Keywords:  Metabolic syndrome; antipsychotics; schizophrenia

Year:  2009        PMID: 19293950      PMCID: PMC2656262          DOI: 10.1002/j.2051-5545.2009.tb00199.x

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  117 in total

1.  Causes of the excess mortality of schizophrenia.

Authors:  S Brown; H Inskip; B Barraclough
Journal:  Br J Psychiatry       Date:  2000-09       Impact factor: 9.319

2.  The changing face of cardiovascular risk.

Authors:  Scott M Grundy
Journal:  J Am Coll Cardiol       Date:  2005-07-05       Impact factor: 24.094

Review 3.  Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria.

Authors:  R I G Holt; R C Peveler
Journal:  Diabetologia       Date:  2006-05-13       Impact factor: 10.122

4.  Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study.

Authors:  Javier Rejas; Julio Bobes; Celso Arango; Pedro Aranda; Rafael Carmena; Margarida Garcia-Garcia
Journal:  Schizophr Res       Date:  2007-12-11       Impact factor: 4.939

5.  Disparities in diabetes care: impact of mental illness.

Authors:  Susan M Frayne; Jewell H Halanych; Donald R Miller; Fei Wang; Hai Lin; Leonard Pogach; Erica J Sharkansky; Terence M Keane; Katherine M Skinner; Craig S Rosen; Dan R Berlowitz
Journal:  Arch Intern Med       Date:  2005 Dec 12-26

Review 6.  Do guidelines for severe mental illness promote physical health and well-being?

Authors:  Leslie Citrome; David Yeomans
Journal:  J Psychopharmacol       Date:  2005-11       Impact factor: 4.153

7.  Medical comorbidity in women and men with schizophrenia: a population-based controlled study.

Authors:  Caroline P Carney; Laura Jones; Robert F Woolson
Journal:  J Gen Intern Med       Date:  2006-11       Impact factor: 5.128

Review 8.  Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.

Authors:  A H Barnett; P Mackin; I Chaudhry; A Farooqi; R Gadsby; A Heald; J Hill; H Millar; R Peveler; A Rees; V Singh; D Taylor; J Vora; P B Jones
Journal:  J Psychopharmacol       Date:  2007-06       Impact factor: 4.153

Review 9.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

Authors:  Sukanta Saha; David Chant; John McGrath
Journal:  Arch Gen Psychiatry       Date:  2007-10

10.  Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey.

Authors:  Jaana M Suvisaari; Samuli I Saarni; Jonna Perälä; Janne V J Suvisaari; Tommi Härkänen; Jouko Lönnqvist; Antti Reunanen
Journal:  J Clin Psychiatry       Date:  2007-07       Impact factor: 4.384

View more
  133 in total

1.  Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.

Authors:  Joseph C Ratliff; Laura B Palmese; Erin L Reutenauer; Vinod H Srihari; Cenk Tek
Journal:  Psychosomatics       Date:  2012-06-02       Impact factor: 2.386

2.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

3.  Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.

Authors:  Vicki L Ellingrod; Stephan F Taylor; Gregory Dalack; Tyler B Grove; Michael J Bly; Robert D Brook; Sebastian K Zöllner; Rodica Pop-Busui
Journal:  J Clin Psychopharmacol       Date:  2012-04       Impact factor: 3.153

4.  The new impact factor of World Psychiatry is 5.562.

Authors: 
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

Review 5.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

6.  Clozapine-induced pericarditis: an ethical dilemma.

Authors:  Harleen Kaur Johal; Alvaro Barrera
Journal:  BMJ Case Rep       Date:  2019-06-20

7.  Physical health care in persons with severe mental illness: a public health and ethical priority.

Authors:  Mario Maj
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

8.  Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia.

Authors:  Omer Saatcioglu; Murat Kalkan; Nurhan Fistikci; Sakire Erek; Kasim Candas Kilic
Journal:  Psychiatr Q       Date:  2016-06

9.  Weight Gain and Its Correlates Among Forensic Inpatients.

Authors:  N Zoe Hilton; Elke Ham; Carol Lang; Grant T Harris
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

10.  The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.

Authors:  Davy Vancampfort; Joseph Firth; Christoph U Correll; Marco Solmi; Dan Siskind; Marc De Hert; Rebekah Carney; Ai Koyanagi; André F Carvalho; Fiona Gaughran; Brendon Stubbs
Journal:  World Psychiatry       Date:  2019-02       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.